Biotricity said that it has wrapped up development of Biopatch, a new ECG patch platform for cardiac patients with fewer complications.

The US medical technology company has developed the new ECG patch platform in a miniaturized form factor having three standard electrodes, with no lead wires.

Biotricity is an extension of the company’s Bioflux device, which has been designed to be used for diagnosing ambulatory patients and for those who are highly prone to adverse heart effects.

Waqaas Al-Siddiq – Biotricity Founder and CEO said: “With development of the patch completed, we’ve achieved the most significant milestone in bringing our product to the market. We took special care to develop our patch platform to ensure that our solution overcomes all of the limitations that other ECG patches in the market currently have.

“It’s with great pride that I can affirm that we have done exactly that. Biopatch will allow us to widen our commercial reach, offering patients a more convenient monitoring solution without compromising diagnostic quality.”

As per the US medical technology company, the new Biopatch ECG patch platform is designed to provide wireless communication to facilitate real-time monitoring of patients.

Additionally, Biopatch is said to ensure advanced conduction and flexibility for all types of skin and through automated wireless uploading, addresses diagnostic and report turn-around problems faced in current patches.

The new ECG patch platform is also rechargeable in order to address battery limitations that are currently faced by other patches in the market.

Presently, the Biopatch ECG patch platform is undergoing internal clinical testing, following which Biotricity plans to submit a 510(k) clearance application to the US Food and Drug Administration (FDA).

  Bioflux, Biopatch, Biotricity, US Food and Drug Administration, Waqaas Al-Siddiq